# Digirad Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/digirad

- Industry: Medical Devices & Equipment
- Headquarters: Suwanee, US
- Website: www.digirad.com
- Total disclosed funding: $27M
- Latest round: Series E (Jan 1, 2001)
- Investors on record: 8

## About

Digirad Corporation focuses on advanced nuclear imaging solutions, providing innovative nuclear medicine cameras for cardiology and general imaging applications, enhancing diagnostic capabilities in healthcare settings.Digirad Corporation specializes in developing nuclear imaging equipment, specifically nuclear medicine cameras. The company is headquartered in Suwanee, US. Digirad was founded to cater to the needs of healthcare providers seeking advanced imaging technology. The current CEO is Dan Koch, who has played a crucial role in the company's strategic direction. In October 2004, Digirad completed a USD 66 mn IPO, marking a significant milestone in its funding history.Digirad specializes in advanced nuclear imaging solutions, primarily offering a suite of innovative nuclear medicine cameras designed for cardiology and general nuclear imaging applications. Their flagship products include the Cardius X-ACT+ and Cardius XPO cameras, which utilize advanced SPECT/FAC technology and are designed for portability and ease of use. These devices provide high-quality imaging while prioritizing patient comfort, making them suitable for a variety of clinical settings, including hospitals and outpatient facilities. Digirad's client base includes healthcare providers and institutions across North America, Europe, and parts of Asia, catering to both pre-existing nuclear medicine departments and new setups seeking state-of-the-art imaging capabilities.For the year 2024, Digirad reported a revenue of USD 53.36 mn and an EBITDA of USD 12.02 mn. The company generates revenue through direct sales of its imaging equipment and related services, with transactions typically structured as B2B engagements with healthcare institutions. Clients engage with the company for one-time purchases of cameras, such as the Cardius X-ACT+, along with ongoing service contracts that provide maintenance and support. These contracts ensure that the imaging systems remain operational and up-to-date, thereby enhancing the value proposition for users.Digirad plans to leverage its recent IPO funding to enhance its product lineup and expand into new markets. The company is focusing on the development of new imaging technologies and aiming to launch these products within the next few years. Additionally, Digirad is targeting expansion into international markets, particularly in Europe and Asia, by 2026 to increase its global footprint. The funding from the USD 66 mn IPO will be utilized to support these initiatives, ensuring that Digirad remains competitive and innovative in the healthcare imaging sector.

## Funding rounds

- Series E, Jan 1, 2001, $21M — Sorrento Ventures, Mitsui Global Investment, Johnson & Johnson Innovation, Vector Fund Management, Indocean Chase Capital Advisors, HCA Healthcare, Inc., Merrill Lynch Ventures, Kingsbury Capital Partners
- Series D, Aug 25, 1997 — Vector Fund Management
- Series C, Oct 21, 1996, $6M — Sorrento Ventures, Kingsbury Capital Partners

## Investors

- Sorrento Ventures (https://capitalatlas.ai/funds/sorrento-ventures) — Series C, Series E
- Kingsbury Capital Partners — Series C, Series E
- Vector Fund Management (https://capitalatlas.ai/funds/vector-fund-management) — Series D, Series E
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series E
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series E
- Indocean Chase Capital Advisors (https://capitalatlas.ai/funds/indocean-chase-capital-advisors) — Series E
- HCA Healthcare, Inc. — Series E
- Merrill Lynch Ventures — Series E